Lilly/Boehringer Duloxetine Co-Promotion Lets Lilly Focus On Cialis Launch
Executive Summary
Lilly and Boehringer Ingelheim's co-promotion agreement for duloxetine in stress urinary incontinence allows Lilly to focus on Cialis while retaining a stake in its duloxetine urology franchise
You may also be interested in...
Yentreve Goes Back To Drawing Board After Lilly/BI Withdraw NDA
Lilly and Boehringer Ingelheim's decision to withdraw the Yentreve application based upon FDA's expected negative review decision will give the companies additional time to develop a marketing strategy
Yentreve Goes Back To Drawing Board After Lilly/BI Withdraw NDA
Lilly and Boehringer Ingelheim's decision to withdraw the Yentreve application based upon FDA's expected negative review decision will give the companies additional time to develop a marketing strategy
Iraq War Rally Helps Rx Stocks; Investors Adjust To Diminished Expectations?
Pfizer's steady progress toward closing the Pharmacia acquisition is giving the company a winning profile on Wall Street against the backdrop of a broader market rally fueled by the U.S. war in Iraq